SCHEMBL4112339

SCHEMBL4112339

Cc1ccc(NC(=O)Nc2ccc(OC(F)F)cc2)cc1C

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
KMT2A Q03164 4/20 0.60
HTT P42858 4/20 0.60
LMNA P02545 3/20 0.60
MEN1 O00255 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
MAPK1 P28482 1/20 0.57
ALDH1A1 P00352 6/20 0.52
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
TSHR P16473 1/20 0.52
RECQL P46063 1/20 0.52
POLB P06746 3/20 0.50
CCNC P24863 1/20 0.50
CDK8 P49336 1/20 0.50
STING1 Q86WV6 1/20 0.50
KDM4E B2RXH2 2/20 0.49
CTDSP1 Q9GZU7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124268 0.89 MAPT (0.57) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4124728 0.89 MAPT (0.57) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4117636 0.89 MAPT (0.57) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4107037 0.87 SMN1; SMN2 (0.66) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4119073 0.87 MAPT (0.56) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4126269 0.87 GLA (0.58) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4118526 0.86 MAPT (0.66) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4116166 0.84 MAPT (0.58) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4121188 0.84 KMT2A (0.59) MAPTKMT2AHTTLMNAMEN1
SCHEMBL4111981 0.83 MAPT (0.59) MAPTKMT2AHTTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885KMT2A 2807/4885HTT 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.